Title: Oligoribonucleotide Derivatives for Specific Inhibition of Gene Expression
Patent Number: 7,635,769
Filed: Sept. 22, 2005
Lead Inventor: Eugen Uhlmann, Sanofi-Aventis
The invention, the patent's abstract states, "relates to oligoribonucleotide derivatives [that] have a 2'5'-linked oligoribonucleotide residue without a 5'-phosphate residue on the 3' end, and to the use thereof for specific inhibition of gene expression."